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for clonal hematopoiesis (CH). Some
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were observed two decades before
expected, with TET2 decreasing in
spaceflight and elevating later post flight.
Thus, CH is an importantmetric for overall
cancer and cardiovascular risk in
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SUMMARY
Clonal hematopoiesis (CH) occurs when blood cells harboring an advantageous mutation propagate faster
than others. These mutations confer a risk for hematological cancers and cardiovascular disease. Here,
we analyze CH in blood samples from a pair of twin astronauts over 4 years in bulk and fractionated cell pop-
ulations using a targeted CH panel, linked-read whole-genome sequencing, and deep RNA sequencing. We
show CH with distinct mutational profiles and increasing allelic fraction that includes a high-risk, TET2 clone
in one subject and two DNMT3A mutations on distinct alleles in the other twin. These astronauts exhibit CH
almost two decades prior to the mean age at which it is typically detected and show larger shifts in clone size
than age-matched controls or radiotherapy patients, based on a longitudinal cohort of 157 cancer patients.
As such, longitudinal monitoring of CHmay serve as an important metric for overall cancer and cardiovascu-
lar risk in astronauts.
INTRODUCTION
The accumulation of DNA mutations in the cells of healthy tis-
sues occurs during normal aging and begins before birth (Blok-
zijl et al., 2016; De, 2011; Vattathil and Scheet, 2016; Vilkki
et al., 2001). While the majority of these mutations are neutral
and do not favor cell expansion (Busque et al., 1996; Genovese
et al., 2014; Jaiswal et al., 2014; Jan et al., 2012; Martincorena
et al., 2015), certain mutations can cause cells to gain a growth
advantage. When such a mutation occurs in the hematopoietic
system and provides some growth advantage to blood cells, it
causes clonal hematopoiesis (CH). The blood cells harboring
this mutation are thought to arise from a single mutated
‘‘clone.’’ While advanced age is associated with higher rates
of CH acquisition, certain environmental exposures such as
cigarette smoke and radiation have been associated with
increased CH as well (Coombs et al., 2017). CH has been
shown to be associated with all-cause mortality (Jaiswal
et al., 2014; Zink et al., 2017).
A proposed functional definition of CH includes the presence
of a dominant somatic mutation at >2% variant allele frequency
(VAF), although a scientifically or clinically relevant lower
threshold remains to be determined (Steensma, 2018). CH can
be pro-inflammatory and, through this mechanism, is thought
to impact cardiovascular health based on data from model sys-
tems and humans (Calvillo-Arg€uelles et al., 2019; Fuster et al.,
2017; Jaiswal et al., 2017; Sano et al., 2018; Wang et al.,
2020). Research has found that the most common mutations
driving CH are in epigenetic modifier genes such as DNMT3A,
TET2, and ASXL1 (Gertz et al., 2020). The known risks of CH
include elevated rates of cardiovascular disease (CVD) and he-
matologic cancer (Calvillo-Arg€uelles et al., 2019). Notably, CH
is associated with a 1.9-fold increase in coronary heart disease
and a 4-fold increase in early-onset myocardial infarction
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(Jaiswal et al., 2017) as well as an 11-fold increase in hematolog-
ic cancer. Case-control studies have shown that CH with
increasedmutational complexity (i.e., >1mutation and/or >1mu-
tation in the same gene) can increase the risk for acute myeloid
leukemia (AML) (Desai et al., 2018), and this finding has been
independently confirmed in men and women (Abelson et al.,
2018).
CH has been studied in elderly twins (>70 years old), revealing
that twin pairs were discordant for CH mutations but with no
obvious genetic predisposition to CH (Hansen et al., 2020). How-
ever, CH has not yet been studied in younger twins or in subjects
who have been exposed to the milieu of space radiation, such as
astronauts. While the presence of CH, by itself, does not consti-
tute a recognized disease condition, it can inform long-term CVD
and cancer risk and thus can serve as a potential useful metric
for astronauts preparing for long-term missions as well as a
definedmetric of acquired somaticmutations. Here, we describe
the such data from astronauts (twin subjects TW and HR, space-
flight and ground control, respectively), including metrics during
a year-long spaceflight mission for the flight subject (Garrett-Ba-
kelman et al., 2019) and results of a 3-year follow-up study.
RESULTS
Individual TW presented at baseline evaluation with a single non-
truncating mutation in TET2 (Cys1273Tyr) at 3.8% VAF, which
corresponds to approximately 1 in 12 affected mononuclear
cells (Figure 1A). The mutation is predicted to be pathogenic ac-
cording to FATHMM and M-CAP mutation scoring, and it was
present in all bulk mononuclear cell collections (Figure 1B) but
absent from T cell populations (CD4, CD8). This lesion was
observed twice in the Catalog of Somatic Mutations in Cancer
(COSMIC) in association with AML, and a TET2 mutation at the
same amino acid (Cys1273Ser) was discovered at 25% VAF in
an 86-year-old female who participated in a recent study of CH
in solid-tumor patients (Coombs et al., 2017). These data sug-
gest a capacity for progression to high-risk CH, and the mutant
clone showed an overall rising VAF trajectory. While in flight,
the mutation clone size remained relatively stable but then
increased to 7.4% after the end of his last year-long International
Space Station (ISS) mission (Garrett-Bakelman et al., 2019). The
variation on VAF over timewasmore pronounced in the 3months
immediately after returning to Earth than during the last 6months
of the space flight (percent deltaVAF [(VAF2–VAF1)/month] was
0.119% versus 0.036%, respectively) (Figure 1A).
It is noteworthy that subject TW was previously diagnosed
with and treated for prostate cancer and that this risk was also
present in his germline DNA as a stop-gain mutation in the RNA-
SEL gene (p.Glu265Ter). Thus, it is likely relevant to compare his
CH data with studies of CH in blood drawn from patients who
were also diagnosed with solid tumors (Coombs et al., 2017).
From this CH cohort (Coombs et al., 2017), the mean age at
which TET2 CH mutations are found in the blood of solid-tumor
patients is 68 years of age (n = 8,810 individuals; Coombs et al.,
2017). Subject TW is therefore exhibiting this mutation nearly two
decades prior to themean age at which it is typically detected (50
versus 68). By comparison, TET2 mutations in blood were de-
tected in only 1% of persons under 55 years of age in the
solid-tumor patient cohort (Coombs et al., 2017), never observed
in a separate control, AML-free population in a previous study
(n = 212) of pre-AML in persons under 65 (Desai et al., 2018),
and also found to be rare (<1%) in another control (n = 678)
cohort (Abelson et al., 2018).
Conversely, the HR subject presented at baseline evaluation
with two mutations in the DNMT3A gene (Figure 1A), which
also were present in B cell (CD19) and T cell (CD4, CD8) popula-
tions (Figure 1B). CH mutations in DNMT3A tend to be loss of
function, arising either from a truncating event such as a frame-
shift or from introduction of a stop codon or a dominant-negative
mutation (Desai et al., 2018). The major DNMT3A mutation
observed in subject HR (Trp698Ter) is a truncating mutation
arising from introduction of a stop codon in DNMT3A, causing
premature termination of the protein at amino acid position
698. This mutation presented at 6.8% VAF, corresponding to
an estimated 1 in 7 affected mononuclear cells. This clone pre-
sented a significant increase during and for the first year after
the end of the flight. After that point, the clone remained stable.
The percent variation in VAF per month for this clone is greater
after the end of the mission (0.304%) compared to in-flight
time points (0.19%).
The second mutation in DNMT3A (Phe732Ser) converts
phenylalanine-732 to serine and initially presented at 2.1%
VAF. Themutation occurs in amutation cluster of the DNAmeth-
ylase domain, thus likely impacting enzymatic function. This mu-
tation was previously observed three times in COSMIC and was
confirmed somatic in both myeloid and lymphoid cancers (Desai
et al., 2018). This mutation was also discovered in one study of
pre-AML in a healthy womanwho later progressed to AML (Desai
et al., 2018). Furthermore, this mutation is predicted to be path-
ogenic according to FATHMM and M-CAP scores. Variation in
VAF during flight was also significant for this mutation, and the
change in dVAF/month was 0.114% during flight versus
0.243% after flight. Finally, a novel somatic mutation in the LPL
gene, which encodes lipoprotein lipase, presented at 1.5%
VAF at baseline evaluation and remained stable to 2020. This
mutation affects the PLAT domain of the protein but is predicted
benign according to variant classification criteria (PolyPhen and
SIFT). Loss-of-function mutations in LPL have been shown to in-
crease macrophage foam cell formation and promote athero-
sclerosis (Babaev et al., 1999). However, the functional impact
of this particular LPL mutation is unknown.
Like his brother, HR was diagnosed and treated for prostate
cancer (tumors were resected for both twins, with no radiation
or chemotherapy) and carried the same risk allele. Thus, it is
also relevant to compare his CH mutations in the context of
the same solid-tumor study of CH (Coombs et al., 2017). Overall,
5% of people under 55 years of age exhibit a single DNMT3A
mutation, and no one in the recent study exhibited two DNMT3A
mutations (Coombs et al., 2017). The mean age of people with
one DNMT3A mutation was 65.8 years. Thus, the fact that sub-
ject HR exhibits two DNMT3A mutations nearly 15 years before
the mean age of onset for a single DNMT3A mutation is poten-
tially significant, and the combined VAF is now above 10%. In
a mutational analysis of a pre-AML cohort (Desai et al., 2018),
two or more DNMT3A mutations were associated with a 12.6-
fold increase in the odds of eventual AML (OR: 12.6, 95% CI




Figure 1. Clonal Hematopoiesis Profiling
(A) Longitudinal trajectories of CH mutations discovered in the astronaut subjects. Allele frequency (%) is the VAF of each clone (vertical axis) visualized across
time (horizontal axis). Subject TW (spaceflight) is compared to subject HR (ground). Flight start and end for the NASA Twins Study are denoted by the gray shaded
region (left). Baseline (2015) time point corresponds to lymphocyte-depletedMNC fraction. Inflight time points and after flight 2016 time points were collected and
processed by density gradient to obtain peripheral blood mononuclear cells, and the 2019 time point corresponds to buffy coat, spun-down blood cells.
(B) VAF in distinct cell populations. The three significant mutations (rows) in DNMT3A and LPL for HR (top) and the two mutations found in subject TW (bottom).
Shown mutations are present in bulk cell populations (bulk), as well as almost all subfractions of T cells (CD4, CD8) and B cells (CD19). VAF range is show in
fraction of color (red to blue, up to 0.1), and asterisks (*) indicate detection of the variant but below 1%. Triangles indicate the beginning and end of the year-long
mission.




3.0–59.2; p < 0.001) compared to a 2.1-fold increase for people
with a single DNMT3A mutation (OR: 2.1, 95% CI 1.2–3.8; p =
0.01). Of note, the RNA sequencing data showed that these
two variants are not expressed on the same allele (Figure S1),
and the linked-read whole-genome sequencing data also
showed no evidence to the two mutations on the same linked-
molecule across four time points (pre-flight 903, mid-flight
943 and 883, and post-flight 773 coverage); thus, these two
mutations are likely from two distinct CH events.
To place these variants into a broader context, the astronaut
CH VAFs were compared to data from a longitudinal CH study
by Bolton and colleagues (Bolton et al., 2019b). This study
compared the effect of oncologic treatment (X-ray radiation
treatment [XRT]) on CH in 49 patients relative to a longitudinal
CH study of 108 controls (n = 157 total). In this cohort, themedian
age of patients with CHwas 68 years old overall and 70 years old
for prostate cancer patients with detected CH (including TET2 or
DNMT3A mutations). Also, the median age for prostate cancer
patients with no detected CH was 65 years old (Bolton et al.,
2019b), and CH was associated with cytotoxic drugs, external
XRT beam radiation, and radionuclide-based therapy. The
most strongly associated genes with oncologic treatment were
those involved in DNA-damage repair (PPM1D, TP53, and
CHEK2). Conversely, DNMT3A or TET2 mutations were not
strongly associated with any tumor type or therapy. Also, pros-
tate cancer was not particularly associated with CH, and no sig-
nificant enrichment of any particular CH gene was observed in
these patients.
However, serial sampling revealed a range of VAF changes in
patients over time, which were often smaller than the astronaut
CH dynamics (Figure 2). Specifically, a subgroup of patients
showed that growth rate of mutations in DTA genes (DNMT3A,
TET2, and ASXL1) was lower than that of DNA damage response
(DDR)-related genes and that the odds of a mutation expanding
after treatment were higher for DDR genes as opposed to DTA
genes. Themean percent variation in VAF permonth was highest
in DDR genes after treatment with external beam radiation
(0.16%) and cytotoxic drugs (0.19%). DNMT3A/TET2 mutations
after radiation treatment presented a mean percent VAF varia-
tion per month higher (0.1%) than any other treatment (range
0.02%–0.08%). While variation in VAF over time for the samples
in this studymay suffer from unique challenges in collection (e.g.,
storage on the ISS and return-to-Earth protocols), it was
possible to estimate such VAF changes within the bulk cell frac-
tions. Interestingly, the variation observed in the astronauts (1%–
2%) was higher than the one observed for DNMT3A/TET2 muta-
tions after oncologic treatment with external beam radiation,
while other variants showed a consistent VAF across all time
points (Figure S2). Ascertaining the significance of such CH
VAF dynamics in astronauts and cancer patients requires larger
cohorts.
DISCUSSION
Currently, there are no evidence-based guidelines for the man-
agement ofCH.However, a set ofmanagement strategies for inci-
dental findings of CH in solid-tumor patients has recently been
suggested (Bolton et al., 2019a). Here, the two astronauts were
found to have mutations in DNMT3A and TET2 consistent with
the presence of CH. People with CHprogress to hematologicma-
lignancies at a rate of 0.5%–1%per year, similar to the rate of pro-
gression of frank neoplasia observed inmonoclonal gammopathy
of uncertain significance (MGUS) or monoclonal B cell lymphocy-
tosis (MBL) (Gertz et al., 2020). However, CH has the potential to
give rise to a broader range of blood cancers than eitherMGUSor
MBL because it usually arises in earlier, less committed hemato-
poietic stem or progenitor cells. While having CH or increased
exposure to radiation are both implicated in higher-risk profiles
for AML, it should be stressed that the absolute risk of the disease
is still low in people in the absence of pre-disposing factors (6 per
100,000 white males per year between ages 50 and 64, SEER
statistics, https://seer.cancer.gov/statistics/).
The factors contributing to these CH variations are unknown
but may include the known conditions of the ISS and spaceflight,
including: reduced gravity, weight loss, baseline genetic risk
(e.g., RNASEL), and increased radiation exposure (including
the 146 mSv for the year-long mission) (Garrett-Bakelman
et al., 2019). While these results are preliminary and require
much larger cohorts for proper interpretation, they nonetheless
have implications for long-term health management. There is
suggestive evidence that people with TET2 mutations exhibit a
1.9-fold risk (95%CI 1.0–3.7; p = 0.06) of coronary heart disease
and 8.3-fold increased odds of myocardial infarction (95% CI
1.2–357.5; p = 0.02). Single TET2 mutations also exhibit
increased odds of AML compared to matched controls (odds ra-
tio: 3.29, 95% CI 1.38–7.83; p = 0.005) (Desai et al., 2018). The
presence of two mutations in DNMT3A in subject HR is sugges-
tive of high-risk CH. The risk of coronary heart disease in patients
exhibiting DNMT3A-mutation-driven CH is 1.7 (95% CI 1.12.6;
p = 0.01), and the pathophysiology of CH in CVD is thought to be
inflammation driven (Calvillo-Arg€uelles et al., 2019). Assuming
the two DNMT3A mutations occur in separate cells, then the
combined VAF of both DNMT3A mutations is 10%. A value
that approaches high-risk CH for CVD (R10%VAF), additionally,
people with a VAFR 10% exhibit a 12-fold increase in the odds
of a coronary artery calcification scoreR 615 Agatson units (OR:
12.1, 95% CI 2.4–64.0; p < 0.001) (Bolton et al., 2019a; Cimmino
et al., 2017). It is unknown how the presence of two DNMT3A
mutations affects the risk of other cancers besides AML.
Prior work on these subjects (Garrett-Bakelman et al., 2019)
noted a range of molecular and physiological changes using a
multimodal and integrated approach, all of which may impact
the overall VAF trajectories. Changes during flight or due to the
stress of returning to Earth were observed for parameters that
could have an impact on CH dynamics, such as spikes in inflam-
mation markers (e.g., IL-6, IL-1ra) (Gertz et al., 2020), T cell func-
tion expression changes (Garrett-Bakelman et al., 2019), and
cytokine shifts (Gertz et al., 2020). Because CH clones both
are pro-inflammatory and expand under inflammatory condi-
tions, it is possible that the fluctuation detected in the levels of
specific cytokines has an effect in the expansion/reduction of
the mutated clones upon returning to Earth. Previous studies
have reported changes in cardiovascular structure and function,
as well as exercise and nutritional differences, which can also be
a factor (Cimmino et al., 2017). Also, of note, TW presented with
signs of vascular remodeling of his carotid artery for the duration




of the flight; this subject presented a mutation in TET2, a gene
that (when mutated) imposes a significant risk to develop CVD.
Therefore, given the changes in the vasculature structure, in-
flammatory cytokines, and gene expression pathways observed
for these individuals, and the association between these param-
eters and CH, it is reasonable to suggest that monitoring of CH
clones, alongside all of these health parameters, should be
included as part of the overall health assessment for astronauts.
Finally, while subject HR exhibits overall higher-risk CH, the
mutation patterns observed in both astronauts are nonetheless
Figure 2. VAF over Time of CH in Astronauts and Cancer Patients
Change in VAF in DNMT3A (A), TET2 (B), CHEK2 (C), PPM1D (D), and TP53 (E) within astronauts (red), cancer patients treated with external beam radiation (blue),
and untreated cancer patients (gray). Identified variants in samples are ordered along the x axis based on their VAF change over two time points (astronauts
baseline versus 3.5 years after flight and cancer patients before and after treatment) with ones decreasing the most on the left (arrow down) and ones increasing
the most on the right (arrow up). Density plots of the variants for each subject group are shown above the line plots.




unusual when considering the relatively young age at which the
mutations are observed (Steensma et al., 2015). The mutations
in both twins had an overall increasing trajectory; however, the
dynamics of the clones was different across time points during
the mission and differed between the two twins. The genesis of
these mutations is unknown, but occupational exposures
received during spaceflight from ages 35–52 and 32–45 for TW
and HR, respectively, are potential factors. Moreover, the differ-
ential rates of these mutations in B cells (CD19) versus T cells
(CD4, CD8) appear to be rare from these data, but it is not known
how this would appear in other cell types and may relate to
distinct risk profiles. Additional data (e.g., red cell distribution
width) would enable improved cancer risk stratification, and
continued evaluation and a longitudinal monitoring plan for
both astronauts could be used to track any change in VAF. These
changes can then be examined relative to published CH guide-
lines (Bolton et al., 2019a; Jaiswal and Ebert, 2019), other CH
data from emerging clinical and control cohorts (Busque et al.,
2012), andmedical guidance fromNASA flight surgeons. Indeed,
when integrated with other health data such as folic acid levels
(Garrett-Bakelman et al., 2019), telomere length (Luxton et al.,
2020a, 2020b), heart morphology (Garrett-Bakelman et al.,
2019), and long-term stress markers for farther missions (Iosim
et al., 2019; Nangle et al., 2020), thesemeasures of CH, including
other changes in physiology (Gertz et al., 2020), could serve as
an additional, quantitative measure of long-term risk of cardio-
vascular and hematological diseases for astronauts before, dur-
ing, and after spaceflight.
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Further information and requests for resources and reagents should be directed to the Lead Contact Christopher E. Mason
(chm2042@med.cornell.edu).
Materials Availability
This study did not generate new unique reagents.
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
CD8 Miltenyi Biotec Cat # 130-097-057
CD4 Miltenyi Biotec Cat # 130-097-048
CD19 Miltenyi Biotec Cat # 130-097-055
Biological Samples
NA12878 Coriell Cat # NA12878
Critical Commercial Assays
4 mL CPT vacutainers BD Biosciences Cat # 362760
KAPA Hyper Prep Library Preparation Roche Cat # 07962347001
Twist Hybridization and Wash Kit Twist Biosciences Cat # 101025
Twist Binding and Purification Beads Twist Biosciences Cat # 100983
10x genomics Chromium Genome kit (2016) 10X Genomics N/A
NEBNext UltraTM II Directional RNA Library Prep Kit New England Biolabs Cat # E7760/E7765
NEBNext rRNA Depletion Kit New England Biolabs Cat # E6310
Deposited Data
Raw and analyzed data This paper NASA LSDA
RNA sequencing Garrett-Bakelman et al., 2019 NASA LSDA
Whole Genome sequencing Garrett-Bakelman et al., 2019 NASA LSDA
Analyzed mutation data on cancer
patients treated with External Beam
radiation or Untreated
Bolton et al., 2019b https://github.com/papaemmelab/
bolton_NG_CH





Gencore v0.13.0 Chen et al., 2019 https://github.com/OpenGene/gencore
fastp v0.20.1 Chen et al., 2018 https://github.com/OpenGene/fastp
BWA MEM v0.7.17 Li, 2013 https://github.com/lh3/bwa
VarDict-Java v1.7.0 Lai et al., 2016 https://github.com/AstraZeneca-
NGS/VarDictJava
Bcftools v1.10.2 Li, 2011 http://samtools.sourceforge.net
Vcflib v1.0.1 Garrison, 2016 https://github.com/vcflib/vcflib
Variant-Effect-Predictor (VEP) v100.3 McLaren et al., 2016 https://github.com/Ensembl/ensembl-vep
LongRanger (1.0.0) N/A https://support.10xgenomics.com/genome-
exome/software/pipelines/latest/installation
Genome Analysis ToolKit (GATK) (4.1.9.0) N/A https://github.com/broadinstitute/gatk/releases
R software N/A https://www.R-project.org/




Data and Code Availability
The NASA Life Sciences Data Archive (LSDA) is the repository for all human and animal research data, including that associated with
this study. LSDA has a public facing portal where data requests can be initiated (https://lsda.jsc.nasa.gov/Request/
dataRequestFAQ). The LSDA team provides the appropriate processes, tools, and secure infrastructure for archival of experimental
data and dissemination while complying with applicable rules, regulations, policies, and procedures governing the management and
archival of sensitive data and information. The LSDA team enables data and information dissemination to the public or to authorized
personnel either by providing public access to information or via an approved request process for information and data from the
LSDA in accordance with NASA Human Research Program and Johnson Space Center (JSC) Institutional Review Board direction.
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human samples
All samples were collected after obtaining written informed consent. Protocols were approved by all participating institutions. Blood
samples from were collected from space and ground subjects into 4 mL CPT vacutainers (BD Biosciences Cat # 362760) as per the
manufacturer’s recommendations. Fresh or frozen samples were processed as described in the NASA Twins Study. Cell population
separation based on CD4, CD8 or CD19markers was performed using column-basedmethod as described in Garrett-Bakelmann et
al. (2019). Astronaut subjects (both male) began the study at age 50.
All subjects were collected under the Weill Cornell Medicine and NASA Institutional Review Board (IRB) protocols, including those
for the NASA Twins Study (IRB#1309014347). For the MSKCC cohort, dosimetric parameters for each course of external beam ra-
diation (i.e., dose, fractionation, 905 technique/modality, target) were extracted from the treatment planning system (ARIA; Varian
Medical Systems, Palo Alto, CA), from radiotherapeutic prescriptions and from clinical treatment summaries. For patients treated
prior to the implementation of contemporary treatment planning (prior to 2003), receipt and timing of radiation therapy was
abstracted from medical billing records, although dose and fractionation were not available for these patients and were set 910
as missing. Other clinical details are online from the Bolton et al. (2019b) paper.
METHOD DETAILS
CH panel, WGS, and RNA-sequencing
Genomic DNA from bulk mononuclear cells (bulk), column-based, purified lymphocytes (CD4, CD8, and CD19) or buffy coat was ex-
tracted, purified, and mechanically sheared using the same protocol as the NASA Twins Study (Garrett-Bakelman et al., 2019). Illu-
mina sequencing adapters containing unique dual sample indices (UDIs) were ligated onto fragments according to the Kapa Bio-
systems HyperPrep protocol. Targeted enrichment using a custom pool of biotinylated baits directed to 93 genes involved in
clonal hematopoiesis, cancer, and CVD was performed according to the standard Twist Biosciences capture protocol. Sequencing
was performed to > 2000x median unique depth of coverage using NovaSeq6000 using 150x150 S4 chemistry. CH detection follows
the strategy employed in our previous study Desai et al. (2018) for quality and filtration of artifacts. Gencore v0.13.0 (Chen et al., 2019)
and fastp v0.20.1 (Chen et al., 2018) were used to trim adaptor sequences and remove duplicates. After alignment with BWA MEM
v0.7.17 (Li, 2013), VarDict-Java v1.7.0 (Lai et al., 2016) was used to call variants on reads. Bcftools v1.10.2 (Li, 2011), SnpEff v4.3 (6),
and Vcflib v1.0.1 (Garrison, 2016) were used to filter out reads for mapping quality, depth, and strand bias. Variant-Effect-Predictor
(VEP) v100.3 (McLaren et al., 2016) was used to annotate variants. NA12878 reference DNAwas included to detect and remove back-
ground. SNP were stringently filtered out when reported as > 0.25% in population allele frequency databases. Variants with VAF R
1% are being reported. The sensitivity of the test is estimated at > 95% for mutations present at VAF > 1% (corresponding to 1/50
mutated cells). Whole genome sequencing (WGS) libraries were prepared with the 10x genomics Chromium Genome kit (2016) and
aligned to the GRCv38 human genome with LongRanger (1.0.0) and supporting files (http://support.10xgenomics.com/
genome-exome/downloads/latest) RNA-sequencing (RNA-seq) were performed with New England Biolabs (NEB) ribo-depletion
RNA-seq and polyA-enrichment kits, as previously described (Garrett-Bakelman et al., 2019), and sequenced Illumina NovaSeq6000
S4 flowcells with 150x150 nt sequencing. Variant calling was completed with the Sentieon instantiation of the Genome Analysis Tool-
Kit (GATK) WGS and RNA-seq variant pipeline (4.1.9.0).
MSK-IMACT Study and Subjects Details
In order to study the growth rate of clonal hematopoiesis mutations over time we collected additional blood samples on patients
sequenced using MSK-IMPACT for repeat CH mutation testing (Bolton et al., 2019b). We extracted data on race, smoking, date
of birth and cancer history through the MSK cancer registry, chemotherapy and radiation therapy through our electronic health re-
cord. We manually reviewed their medical records to capture receipt of oncologic therapy received at outside institutions during the
follow-up period. If subjects received therapy outside MSK during the follow-up period, we excluded them from analyses of dose-
response relationships since cumulative dose of therapy could not be consistently collected from outside records. This study was
approved by the MSKCC Institutional Review Board. Subjects had a tumor and blood sample (as a matched normal) sequenced us-
ingMSK-IMPACT, a FDA-authorized hybridization capture-based next-generation sequencing assay encompassing all protein-cod-
ing exons of cancer-associated genes. MSK-IMPACT is validated and approved for clinical use by New York State Department of




Health Clinical Laboratory Evaluation Program and is used to sequence cancer patients atMemorial Sloan Kettering. GenomicDNA is
extracted from de-paraffinized formalin fixed paraffin embedded (FFPE) tumor tissue and patient matched blood sample, sheared
and DNA fragments were captured using custom probes. The blood samples in the serial sampling cohort that were obtained for
repeat CH testing were sequenced using a comparable capture-based custom panel using 163 genes implicated in myeloid path-
ogenesis, which included the most commonly mutated genes in our MSK-IMPACT study and this study here, with the exception of
ATM. The median sequencing depth was 665X (range = 111-1987X) which was comparable to that obtained in the blood using MSK-
IMPACT. We only consideredmutations that were present in both the initial and follow-up panel and related to the CH panel for these
astronaut samples.
Dosimetric parameters for each course of external beam radiation for each patient (i.e., dose, fractionation, technique/modality,
target, n = 157 total, including 49 XRT samples) were extracted from the treatment planning system (ARIA; Varian Medical Systems,
Palo Alto, CA), from radiotherapeutic prescriptions and from clinical treatment summaries. For patients treated prior to the implemen-
tation of contemporary treatment planning (prior to 2003), receipt and timing of radiation therapy was abstracted frommedical billing
records, although dose and fractionation were not available for these patients and were set as missing. Given the variety of radio-
therapy fractionation schemes and prescribed tumor doses, we calculated the cumulative radiation dose received by each patient
prior to blood draw in 2-Gy per fraction equivalents (EQD2) using an a/b of 3 Gy, considering CH to be a late-responding tissue effect.
We calculated tertiles of dose based on the distribution of cumulative EQD2 received over the entire cohort and assigned each in-
dividual a score based on their tertile of exposure (e.g. a patient who did not receive external beam radiation received a score of
zero for that particular agent. If the patient’s cumulative radiation dose, as expressed in EQD2, was within the first tertile, a score
of one was assigned, and so forth). The twins were selected by NASA, since they were the only twin astronauts on Earth.
QUANTIFICATION AND STATISTICAL ANALYSIS
Analysis was conducted in R environment (https://www.R-project.org; R: A language and environment for statistical computing. R
Foundation for Statistical Computing, Vienna, Austria). Figures were produced using the package ggplot2 also in R (Wickham,
2016). Statistical significance was defined as p < 0.05. Statistical tests were performed using R software.
As per the procedure in Bolton et al., we used a linear model for VAF changes. For each mutation in each individual with sequential
sequencing data available, we modeled the growth rate of the mutation between the two time points according to the following for-
mula: a = log (V / V0) / (T - T0) Where T and T0 indicates the age of the individual (in days) at the two measurement time points and V
and V0 correspond to the VAF at T and T0 respectively.We also classifiedmutations as 600 having increased, decreased or remained
constant during the follow-up period based on a binomial test comparing the two VAFs. Generalized estimating equations were used
to test for an association between exposure to cytotoxic therapy and external beam radiation therapy and CH growth rate adjusting
for age, gender and smoking status accounting for correlation between the growth rate of mutations in the same person. Among pa-
tients with at least one mutation in a 605 DDR CH gene and another non-DDR CH gene (N = 34), we calculated the difference in the
growth rate betweenmutations. When patients hadmore than twomutations in the same gene category, we used the highest growth
rate for that category. A paired t test was used to test for significance in the difference between growth rates of DDR mutations
compared to non-DDR mutations within individuals who received cytotoxic therapy and/or external beam radiation 610 therapy
and within those who were untreated during the follow-up period.
ADDITIONAL RESOURCES
Additional details are on NASA’s sites including http://www.nasa.gov/twins-study/.
List of Genes in CH Panel (n = 93)
ACTA2, ACTC1, ANGPTL4, ANKRD26, APC, APOA5, APOB, APOC3, ASXL1, ATM, BAP1, BARD1, BMPR1A, BRAF, BRCA1,
BRCA2, BRIP1, CBL, CDH1, CDK4, CDKN2A, CEBPA, CHEK2, COL3A1, DDX41, DNMT3A, DSC2, DSG2, DSP, EPCAM, ETV6,
FBN1, FLT3, GATA1, GATA2, GLA, GREM1, IDH1, IDH2, JAK2, KCNH2, KCNQ1, KDM1A, KRAS, LDLR, LMNA, LPA, LPL, MITF,
MLH1, MPL, MSH2, MSH6, MUTYH, MYBPC3, MYH11, MYH7, MYL2, MYL3, NBN, NPC1L1, NPM1, NRAS, PALB2, PCSK9,
PKP2, PMS2, POLD1, POLE, PPM1D, PRKAG2, PTEN, RAD51C, RAD51D, RUNX1, RYR2, SCN5A, SF3B1, SMAD3, SMAD4,
SRP72, SRSF2, STK11, TET2, TGFBR1, TGFBR2, TMEM43, TNNI3, TNNT2, TP53, TPM1, U2AF1, ZRSR2
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